Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results

Abstrakt

Reported here are 72 previously treated Philadelphia chromosome-positive CML patients on imatinib (IM) therapy, with a focus on patients with additional chromosomal aberrations. The present results confirm that the majority of previously treated Ph+ CML patients benefit from starting IM therapy, including patients with defined additional changes.

In contrast, patients with complex karyotype have poor prognosis, even with IM.